Loading clinical trials...
Loading clinical trials...
The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279. A...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Takeda
NCT06100991 · Generalized Pustular Psoriasis
NCT06477536 · Generalized Pustular Psoriasis
NCT07448428 · Generalized Pustular Psoriasis, Generalized Pustular Psoriasis (GPP)
NCT06886009 · Generalized Pustular Psoriasis
NCT07314060 · Generalized Pustular Psoriasis
Nagoya City University Hospital
Nagoya, Aichi-ken
Fujita Health University Hospital
Toyoake, Aichi-ken
Kimitsu Chuo Hospital
Kisarazu, Chiba
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions